Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival
Pooled Analysis of 12 Seperate Yervoy Studies Shows Survival-Curve Plateau at 3 Years
Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer
ASCO and CAP Issue Guideline To Improve HER2 Testing
Phase III Ramucirumab Trial Fails Primary Endpoint of PFS
Kadcyla Extends Median PFS In Open-Label Phase III Trial
Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease
Colon Polyps in Elderly Patients Are More Likely to Be Found Only with Colonoscopy
Phase III Vaccine Trial Fails To Improve Overall Survival
Central Line Safety Intervention Lowers Patient Infection Rate
Phase II Study Shows Positive Results in Reducing Dry Mouth
NCI CTEP Approved Trials For the Month of October
Trending Stories
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
